Global Cetuximab Market is segmented, by Geographical Region into United States, China, Europe, and Japan. Cetuximab comes across as an epidermal growth factor receptor (EGFR) inhibitor used to treat metastatic non-small cell lung cancer, head and neck cancer, and metastatic colorectal cancer.

Owing to the collection of the EGFR-dependent intracellular signal pathways, the biological effects of the blockade of ligand receptor binding by cetuximab are wide-ranging. In preclinical in vitro and in vivo studies, it has been shown that cetuximab acts as a constraint to tumor development and metastasis. EGFR is articulated in many normal epithelial tissues including skin and hair follicles in the Cetuximab Market.

[b]Browse Detail Market Report @[/b] [url=http://www.prfree.org/] https://www.millioninsights.com/industry-reports/cetuximab-market[/url]

Cetuximab is dispatched under the trade name “Erbitux” in the U.S. and Canada by the drug company Bristol-Myers Squibb and outside the U.S. and Canada by the drug company Merck KGaA. In Japan, Merck Group, Bristol-Myers Squibb and Eli Lilly have a co-distribution.

In July 2009, the FDA did approve cetuximab (Erbitux) for treating colon cancer with wild-type KRAS, since it had negligible effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab). This was the first genetic test to guide treatment of cancer. In July 2012, the FDA permitted a real-time PCR companion diagnostic test for KRAS, the Thera screen KRAS test.

[b]Request Sample Copy of Market Research @[/b] [url=http://www.prfree.org/]https://www.millioninsights.com/industry-reports/cetuximab-market/request-sample[/url]

A diagnostic immunohistochemistry assay (EGFR pharmDx) can be used to notice EGFR expression in the tumor material. More than half of patients with metastatic colorectal cancer have an EGFR-expressing tumor and are therefore eligible for treatment by cetuximab or panitumumab, adhering to FDA guidelines. Cetuximab Market is segmented, by Function into tumor growth and metastasis Proliferation, cell survival, cell motility, cell invasion, tumor angiogenesis, and deoxyribonucleic acid (DNA) repair.

Cetuximab Market is segmented, by Uses into Metastatic Colorectal Cancer (cancer spread beyond the colon or rectum), Squamous Cell cancer of head and neck, Non-small cell lung cancer, Squamous cell skin cancer. Cetuximab Market Key Players include Pfizer, Allergan, Alnylam Pharmaceuticals, Amgen, Angstrom Pharmaceuticals, Acceleron Pharma, Biocon, Bionomics, CASI Pharmaceuticals, Celgene Corporation, Enzon Pharmaceuticals, Five Prime Therapeutics, Fujifilm Kyowa Kirin Biologics, Genentech, Genexine, Hetro Drugs, Kyowas Hakko Kirin

[b]About Us:[/b]

At [b]Million Insights[/b], we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

[b]Contact Information:[/b]
[b]Ryan Manuel[/b]
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-408-610-2300
Email Us: [b][email protected][/b]
Our Website: [b][color=#ff0000]https://www.millioninsights.com/[/color][/b]
Visit our Blog:[b][color=#ff0000]www.millioninsights.blogspot.com[/color][/b]